Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- General Biostatistics (2)
- Bayesian modeling; genomics; hierarchical models; integrative analysis; sparsity priors (1)
- Brain eff (1)
- Cancer (1)
- Colon cancer (1)
-
- Exact testing (1)
- Familial adenomatous polyposis (1)
- Functional Connectivity (1)
- Gastroenterology (1)
- Genomics (1)
- Logistic regression (1)
- Receiver operating characteristic curve (1)
- Risk reclassification (1)
- Simes; Bonferroni; closed testing principle (1)
- Statistical Theory and Methods (1)
- Web-based tool (1)
Articles 1 - 6 of 6
Full-Text Articles in Biostatistics
Hierarchical Vector Auto-Regressive Models And Their Applications To Multi-Subject Effective Connectivity, Cristina Gorrostieta, Mark Fiecas, Hernando Ombao, Erin Burke, Steven Cramer
Hierarchical Vector Auto-Regressive Models And Their Applications To Multi-Subject Effective Connectivity, Cristina Gorrostieta, Mark Fiecas, Hernando Ombao, Erin Burke, Steven Cramer
Mark Fiecas
Global Quantitative Assessment Of The Colorectal Polyp Burden In Familial Adenomatous Polyposis Using A Web-Based Tool, Patrick M. Lynch, Jeffrey S. Morris, William A. Ross, Miguel A. Rodriguez-Bigas, Juan Posadas, Rossa Khalaf, Diane M. Weber, Valerie O. Sepeda, Bernard Levin, Imad Shureiqi
Global Quantitative Assessment Of The Colorectal Polyp Burden In Familial Adenomatous Polyposis Using A Web-Based Tool, Patrick M. Lynch, Jeffrey S. Morris, William A. Ross, Miguel A. Rodriguez-Bigas, Juan Posadas, Rossa Khalaf, Diane M. Weber, Valerie O. Sepeda, Bernard Levin, Imad Shureiqi
Jeffrey S. Morris
Background: Accurate measures of the total polyp burden in familial adenomatous polyposis (FAP) are lacking. Current assessment tools include polyp quantitation in limited-field photographs and qualitative total colorectal polyp burden by video.
Objective: To develop global quantitative tools of the FAP colorectal adenoma burden.
Design: A single-arm, phase II trial.
Patients: Twenty-seven patients with FAP.
Intervention: Treatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring.
Main Outcome Measurements: Global adenoma counts and sizes (grouped into categories: less than 2 mm, 2-4 mm, and greater than 4 mm) were …
On The Exact Size Of Multiple Comparison Tests, Chris Lloyd
On The Exact Size Of Multiple Comparison Tests, Chris Lloyd
Chris J. Lloyd
No abstract provided.
An Overview Of Targeted Maximum Likelihood Estimation, Susan Gruber
An Overview Of Targeted Maximum Likelihood Estimation, Susan Gruber
Susan Gruber
These slides provide an introduction to targeted maximum likelihood estimation in a point treatment setting.
Bayesian Methods For Expression-Based Integration, Elizabeth M. Jennings, Jeffrey S. Morris, Raymond J. Carroll, Ganiraju C. Manyam, Veera Baladandayuthapani
Bayesian Methods For Expression-Based Integration, Elizabeth M. Jennings, Jeffrey S. Morris, Raymond J. Carroll, Ganiraju C. Manyam, Veera Baladandayuthapani
Jeffrey S. Morris
We propose methods to integrate data across several genomic platforms using a hierarchical Bayesian analysis framework that incorporates the biological relationships among the platforms to identify genes whose expression is related to clinical outcomes in cancer. This integrated approach combines information across all platforms, leading to increased statistical power in finding these predictive genes, and further provides mechanistic information about the manner in which the gene affects the outcome. We demonstrate the advantages of the shrinkage estimation used by this approach through a simulation, and finally, we apply our method to a Glioblastoma Multiforme dataset and identify several genes potentially …
Methods For Evaluating Prediction Performance Of Biomarkers And Tests, Margaret S. Pepe Phd, Holly Janes Phd
Methods For Evaluating Prediction Performance Of Biomarkers And Tests, Margaret S. Pepe Phd, Holly Janes Phd
Margaret S Pepe PhD
This chapter describes and critiques methods for evaluating the performance of markers to predict risk of a current or future clinical outcome. We consider three criteria that are important for evaluating a risk model: calibration, benefit for decision making and accurate classification. We also describe and discuss a variety of summary measures in common use for quantifying predictive information such as the area under the ROC curve and R-squared. The roles and problems with recently proposed risk reclassification approaches are discussed in detail.